StockData

Ainos vs Cardio Diagnostics

AIMD and CDIO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AIMD and CDIO compare

Cardio Diagnostics is the larger company, worth 1.6 times as much as Ainos ($5.7M against $3.6M).

Cardio Diagnostics keeps more of each dollar of sales as profit, with a net margin of −42722% compared with −106283% at Ainos.

Cardio Diagnostics scores higher on the StockData Score (4 against 1 for Ainos), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAIMDCDIO
Size and price
Market cap$3.6M$5.7M
Share price$0.485$1.92
Change, 1 year−82.7%−50.3%
Change, 5 years−99.8%–
Beta (5Y)2.532.65
Employees417
StockData Score
Total score14 (better)
Valuation score11
Growth score01 (better)
Performance score01 (better)
Health score01 (better)
Dividend score00
Valuation
P/S263× (better)374×
P/B1.1×1.0× (better)
FCF yield−126%−102% (better)
Growth
Revenue growth (TTM)−87.7%–
Revenue growth, 5Y average49.6%–
Profitability
Gross margin78.7%–
Operating margin−101210%−42650% (better)
Net margin−106283%−42722% (better)
FCF margin−33047% (better)−38091%
Return on equity−196%−93.5% (better)
Return on invested capital−180%−136% (better)
Financial health
Interest coverage−18.8× (better)−564.9×
Current ratio0.1317.44 (better)
Altman Z-score−8.39−1.27 (better)
Piotroski F-score4 (better)2
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions3.4%24.3%
Held by insiders–2.7%
Insider net buying, 12 months−$469K–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.